Richard Lloyd US Senator Orrin Hatch has introduced a legislative amendment which would prevent generic drug companies from challenging brand-name drug patents using both the Hatch-Waxman and an inter partes review (IPR) routes. Instead, they would be forced to choose which of the two procedures that are currently available to them to use.  IPR has proved to...

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Your magazine is great; a timely and eminently worthwhile read.

Mark S Holmes
Chief executive officer
PatentBridge LLC

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?